Ideaya Biosciences Inc
$ 31.67
-1.25%
25 Feb - close price
- Market Cap 2,781,070,000 USD
- Current Price $ 31.67
- High / Low $ 32.95 / 31.58
- Stock P/E N/A
- Book Value 11.65
- EPS -1.28
- Next Earning Report 2026-03-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.11 %
- 52 Week High 39.28
- 52 Week Low 13.45
About
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Analyst Target Price
$50.06
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-07 | 2023-08-10 | 2023-05-09 | 2023-03-07 |
| Reported EPS | 1.33 | -0.88 | -0.82 | -1.49 | -0.6 | -0.68 | -0.53 | -0.52 | -0.46 | -0.5 | -0.49 | -0.5 |
| Estimated EPS | -0.55 | -0.79 | -0.69 | -0.6225 | -0.63 | -0.54 | -0.51 | -0.47 | -0.49 | -0.56 | -0.55 | -0.56 |
| Surprise | 1.88 | -0.09 | -0.13 | -0.8675 | 0.03 | -0.14 | -0.02 | -0.05 | 0.03 | 0.06 | 0.06 | 0.06 |
| Surprise Percentage | 341.8182% | -11.3924% | -18.8406% | -139.3574% | 4.7619% | -25.9259% | -3.9216% | -10.6383% | 6.1224% | 10.7143% | 10.9091% | 10.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-31 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.937 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IDYA
2026-02-25 11:50:00
Ideaya Biosciences Inc. (NASDAQ: IDYA) shows positive near-term sentiment but a weak mid-term bias within a strong long-term context, with current elevated downside risk. AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. The analysis provides multi-timeframe signal strengths, support, and resistance levels for the stock.
2026-02-25 10:52:56
Ideaya Biosciences has announced that the first patient has been dosed in its Phase 1 trial for IDE034. This drug is a potential first-in-class B7h3/PTK7 bispecific TOP1 ADC. The company is advancing this promising new therapeutic candidate.
2026-02-25 10:52:55
IDEAYA Biosciences announced the enrollment of the first patient in its Phase 1 clinical trial for IDE034, a B7H3/PTK7 bispecific TOP1 ADC designed for certain solid tumors. This milestone triggers a $5 million payment to Biocytogen and marks a step forward in IDEAYA's strategy to develop new ADCs, both as monotherapy and in combination with DNA damage response pathway inhibitors like IDE161. The drug holds promise for patients with lung, breast, ovarian, and colorectal cancers where these antigens are co-expressed.
2026-02-24 19:52:56
IDEAYA Biosciences has appointed Dr. Theodora Ross as its Chief Development Officer to lead early clinical development for its oncology pipeline and contribute to R&D strategy. Dr. Ross brings extensive experience from AbbVie, Amgen, and Merck, having advanced several clinical-stage oncology programs and overseen a major acquisition. The company is also anticipating topline progression-free survival data from a Phase 2/3 trial and regaining rights to two clinical programs from GlaxoSmithKline.
2026-02-23 19:52:56
IDEAYA Biosciences (Nasdaq: IDYA) has appointed Dr. Theodora (Theo) Ross, an experienced oncology leader from AbbVie, as its new Chief Development Officer, effective February 23, 2026. In this role, Dr. Ross will spearhead early clinical development for IDEAYA's oncology pipeline and guide its long-term R&D strategy. Her extensive background includes advancing multiple clinical programs and contributing to a significant acquisition, bringing valuable expertise to IDEAYA's precision medicine efforts.
2026-02-23 18:20:58
IDEAYA Biosciences expects to release top-line data for its darovasertib plus crizotinib trial in metastatic uveal melanoma by the end of March 2026, with a formal OS interim analysis planned for early 2027. The company is also expanding darovasertib into earlier-stage uveal melanoma settings and progressing several ADC programs, aiming for a cash runway into 2030 with approximately $1.05 billion in cash. Key upcoming milestones include an initial phase 1 data update for its DLL3 TOPO1 ADC by year-end and data for the MTAP combination (IDE397 + Trodelvy) in 2026.
